Media stories about Assembly Biosciences (NASDAQ:ASMB) have trended positive on Saturday, according to AlphaOne Sentiment. The research firm, a unit of Accern, identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Assembly Biosciences earned a media sentiment score of 0.31 on AlphaOne’s scale. AlphaOne also gave media headlines about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the company’s share price in the near term.
Assembly Biosciences (NASDAQ:ASMB) traded down 0.04% on Friday, hitting $23.32. The company’s stock had a trading volume of 33,005 shares. The company has a 50 day moving average price of $23.65 and a 200-day moving average price of $18.91. Assembly Biosciences has a 1-year low of $5.00 and a 1-year high of $28.18. The company’s market capitalization is $404.51 million.
ILLEGAL ACTIVITY WARNING: “Assembly Biosciences (ASMB) Receiving Positive Media Coverage, Report Shows” was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2017/05/20/assembly-biosciences-asmb-receiving-positive-media-coverage-report-shows.html.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.